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Abstract  
The members of the organic anion transporting polypeptide superfamily (OATPs) are 
classified within the SLCO solute carrier family. All functionally well characterized members 
are predicted to have 12 transmembrane domains and are sodium-independent transport 
systems that mediate the transport of a broad range of endo- as well as xeno-biotics. 
Substrates are mainly amphipathic organic anions with a molecular weight of more than 300 
Da, but some of the known transported substrates are also neutral or even positively charged. 
Among the well characterized substrates are numerous drugs including statins, ACE 
inhibitors, angiotensin receptor blockers, antibiotics, antihistaminics, antihypertensives and 
anticancer drugs.  Based on their amino acid sequence identities, the different OATPs cluster 
into families (in general with more than 40% amino acid sequence identity) and subfamilies 
(more than 60% amino acid identity). With the sequencing of genomes from different species 
and the computerized prediction of encoded proteins more than 300 OATPs can be found in 
the databases, however only a fraction of them have been identified in humans, rodents, and 
some additional species important for pharmaceutical research like the rhesus monkey 
(Macaca mulatta), the dog (Canis lupus familiaris) and the pig (Sus scrofa). These OATPs 
form 6 families (OATP1–OATP6) and 13 subfamilies. In this review we try to summarize 
what is currently known about OATPs with respect to endogenous substrates, tissue 
distribution, transport mechanisms, regulation of expression, structure-function relationship 
and mutations and polymorphisms.   
 
1. Introduction 
Cells continuously need to take up nutrients as well as signaling molecules and to release 
metabolic endproducts for disposal. Most such substances, even if very lipopophilic, are not 
able to diffuse across plasma membranes and consequently need transport proteins to cross 
the cell boundaries. This is exemplified by cholesterol, which takes advantage of (transport) 
proteins to cross plasma membranes. For example, cholesterol absorption in the small 
intestine is mediated, at least in part, by the Niemann-Pick 1-like 1 (NPC1L1) protein (Lecerf 
and de Lorgeril, 2011), which is susceptible to inhibition by the drug ezetimibe. Else, release 
of cholesterol from the canalicular membrane of hepatocytes into bile is facilitated by the 
heterodimeric ATP-binding-cassette (ABC) transporter ABCG5/ABCG8 (Hazard and Patel, 
2007). Bilirubin, the metabolic endproduct of the breakdown of heme, is practically water 
insoluble and has for a long time been assumed to enter hepatocytes by simple diffusion. 
While the issue of transmembrane movement of bilirubin was controversially discussed 
  
(diffusion across lipid bilayer versus involvement of protein(s) (Ostrow et al., 1994)), several 
groups have now provided solid evidence for the involvement of organic anion transporting 
polypeptides (OATPs) in bilirubin uptake into hepatocytes (see below). From these prototypic 
results, it is safe to extrapolate that most substances and even highly non-polar or lipophilic 
compounds require transmembrane transport proteins to be moved between the extracellular 
space and the cytoplasm. The importance of transport proteins in the disposition of drugs is 
also gaining wide acceptance (Dobson et al., 2009; Fenner et al., 2012). The solute carrier 
superfamily (SLC) covers hundreds of proteins mediating the plasma membrane crossing of 
small molecules or solutes of various degrees of hydrophilicity and lipophilicity (Hediger et 
al., 2004). Among the SLC superfamily members, OATPs play a prominent role in 
transporting endo- as well as xeno-biotics including numerous drugs across plasma 
membranes. 
 
In recent years, considerable progress has been made in identifying endogenous substrates of 
OATPs, in elucidating the roles OATPs play in drug disposition and transport of toxins, as 
well as in the characterization of genetic variants. In this overview on the current status of 
OATP research, we do not attempt to summarize the so far characterized drugs and 
xenobiotics, which have been identified as OATP substrates as this information can be found 
in several recent reviews (Fahrmayr et al., 2010; Giacomini et al., 2010; Hagenbuch and Gui, 
2008; Kalliokoski and Niemi, 2009; Konig, 2011; Kusuhara and Sugiyama, 2009; Roth et al., 
2012). 
 
2. Phylogenesis of OATPs: 
The first OATP, rat OATP1A1 (originally called Oatp) was isolated in 1994 using expression 
cloning (Jacquemin et al., 1994) and the first human OATP, OATP1A2 (originally called 
OATP) was isolated a year later by hybridization screening (Kullak-Ublick et al., 1995). In 
the following years several additional OATPs from humans and rodents were identified and 
characterized and we know today that there are eleven OATPs in humans. In 2004, an amino 
acid sequence based classification and nomenclature system was introduced and approved by 
the HUGO Gene Nomenclature Committee (Hagenbuch and Meier, 2004). This classification 
system allows us to name any newly identified OATP with a unique name if it is a unique 
member of the family or with the name of its already known orthologue. The general rules for 
this classification system are that proteins with more than 40 % identity belong to the same 
family while proteins with more than 60 % identity belong to the same subfamily (Hagenbuch 
  
and Meier, 2004). On this basis, the human and rodent OATPs form 6 families (OATP1, 
OATP2, OATP3, OATP4, OATP5, and OATP6) and each family can have subfamilies (e.g. 
OATP1A, OATP1B, OATP1C). Within these subfamilies the individual OATPs are 
numbered according to the chronology of their identification and if there is already an 
orthologue known they are given the same number. The symbols for human and rodent 
proteins are always given in capitals (e.g. OATP1A2). The corresponding gene symbols begin 
with SLCO for human and Slco for rodents and have the same family number, subfamily letter 
and chronological number as the protein symbol (e.g. SLCO1A2 for OATP1A2, Slco1a1 for 
mouse OATP1A1). In contrast to protein symbols, gene symbols are always given in italics. 
However, it turned out that the 40% and 60% are not absolute numbers because e.g. X. laevis 
oatp1a2 has only 48% amino acid sequence identity to human OATP1A2 but based on 
phylogenetic analysis clearly is an orthologue of human OATP1A2 and does not belong to the 
1B or 1C subfamily. Thus, newly identified OATPs should be carefully classified before a 
new name is assigned. The currently approved human members of the SLCO superfamily are 
summarized in Table 1. In the transporter classification database maintained by Milton Saier 
OATPs are found in the "The Organo Anion Transporter (OAT) Family" 2.A.60 (Saier et al., 
1999). 
 
Compared to the 52 members of the OATP superfamily reported in 2004, today more than 
300 members have been identified and/or predicted from over 40 species. Figure 1 shows the 
phylogenetic tree of 70 OATPs from human, monkey, dog, pig, rat and mouse. The OATP1 
family is the largest with 27 members, followed by the OATP6 family. In both families gene 
duplications in rodents resulted in several genes/proteins for rats and mice as compared to 
humans, while in subfamily OATP1B a gene duplication resulted in two genes/proteins for 
humans and monkeys (OATP1B1 and OATP1B3 as compared to rodent OATP1B2 or 
OATP1B4). The OATP3 family has the most conserved members with amino acid sequence 
identities between 94 and 99 % while the OATP6 family is the most diverged. It is interesting 
to note that no OATP homologues have been found in bacteria or yeast suggesting that 
OATPs are specific to the animal kingdom. 
 
3. Endogenous substrates of OATPs 
Murine OATP1A1, the founding member of the SLCO superfamily of organic anion 
transporters, was isolated with an expression-cloning approach using the anion 
bromosulphophthalein as substrate (Hagenbuch and Meier, 2004; Jacquemin et al., 1994). 
  
Functional characterization of OATP1A1 in heterologous expression systems revealed that it 
can transport bile acids (e.g. cholate) and bile acid conjugates (e.g. taurocholate) (Eckhardt et 
al., 1999; Jacquemin et al., 1994) in a sodium-independent way with a preference for 
unconjugated over conjugated bile acids (Meier et al., 1997). Hence, bile salts can be 
considered the first identified endogenous OATP substrates. OATP1A2 can also transport 
unconjugated and conjugated bile acids (Table 2) (Kullak-Ublick et al., 1995). In addition, 
OATP1A2 can also transport dehydroepiandrosterone sulfate, a precursor for the synthesis of 
steroid hormones in many organs (Kullak-Ublick et al., 1998). Later, OATP1B1 (Abe et al., 
1999), OATP1A2 and OATP4A1 (Fujiwara et al., 2001), OATP1C1 (Pizzagalli et al., 2002) 
and OATP3A1_v1 (Huber et al., 2007) were also found to transport thyroid hormones (Jansen 
et al., 2005). Additional endogenous OATP substrates are listed in Table 2. 
 
To date, no severe human diseases related to bile salt homeostasis, to thyroid hormone 
biogenesis and metabolism or to steroid hormone synthesis have been linked to mutations in 
genes coding for various OATPs. Consequently, generation of Slco knockout mice was 
required to more directly prove and study the physiologic roles of OATPs in handling of 
endogenous substrates. Mammalian hepatocytes express two (humans) or three (rodents) 
different OATPs, which are members of the SLCO families 1A and 1B, respectively 
(Hagenbuch and Meier, 2004). The genes encoding these OATPs are clustered on human 
chromosome 12 and on mouse chromosome 6. Mice with a disrupted locus for Slco1a/1b 
subfamily members are vital and display no obvious disease phenotype, but have mildly 
elevated serum bile salt levels, supporting a role for OATPs in the hepatic uptake of bile salts 
(van de Steeg et al., 2010). Importantly, analysis of the bile salt pattern in the serum of these 
knock-out animals revealed unchanged levels of conjugated bile acids compared to the parent 
mouse strain but 13-fold elevated serum levels of unconjugated bile acids (van de Steeg et al., 
2010). These findings were confirmed by another research group, which also reported 
elevated unconjugated bile acids but normal conjugated bile acids in mice with a disrupted 
Slco1b2 gene (Csanaky et al., 2011). This latter finding is remarkable, as in general OATPs 
have overlapping substrate specificities (Table 2) and all rat orthologues of the mouse liver 
OATPs have been shown to transport bile salts in heterologous expression systems (Leuthold 
et al., 2009). Hence, in vivo, despite the coexpression of several OATPs in the same cells such 
as hepatocytes, a specific OATP may be required for the transport of a given substrate. If such 
an OATP is nonfunctional like in a knock-out mouse model or a human disease, the other 
OATPs do not seem to be capable in all instances to fully compensate for the loss of such 
  
transport activity. After cloning of the human hepatocellular OATPs, two groups reported that 
OATP1B1 and OATP1B3 could mediate the transport of unconjugated bilirubin (Briz et al., 
2003; Cui et al., 2001)(Table 2). Serum analysis of the knock-out mice lacking the 
OATP1A/1B family members revealed hyperbilirubinemia (van de Steeg et al., 2010). These 
animals display more than 40-fold elevated serum levels of total bilirubin compared to wild-
type mice. About 95 % of the increased bilirubin was due to bilirubin mono- and bis-
glucuronide, but also unconjugated bilirubin was elevated about 2.5-fold. Hence, this 
observation supports the concept that hepatocellular OATPs are involved in the transport of 
unconjugated and conjugated bilirubin into hepatocytes. Again, mice with an inactivated 
Slco1b2 gene also have a mild hyperbilirubinemia (Csanaky et al., 2011; Zaher et al., 2008) 
suggesting that in mice, OATP1B2 plays a major role in bilirubin handling. The impact of the 
thyroid hormone transporter OATP1C1 on the disposition of thyroid hormones has lately been 
studied in knock-out mice. These animals have no alterations in their serum levels of thyroid 
hormones and their metabolites, but display reduced thyroxin levels and altered expression of 
deiodinases in their brains (Mayerl et al., 2012). These examples illustrate that knock-out 
mice are a powerful tool in the identification of endogenous or physiologic substrates of 
OATPs as well as in the explanation of human diseases with unknown etiology. 
 
4. Tissue distribution 
The expression of OATPs has been studied both at the mRNA and the protein level. In 
general, OATPs have been detected in essentially every organ in epithelial or endothelial 
cells. Some OATPs have a restricted expression and are therefore assumed to be organ 
specific, while others are expressed ubiquitously. Examples for such a restricted expression 
are the two human transporters OATP1B1 and OATP1B3 that are considered to be liver-
specific (Roth et al., 2012) or the brain-specific OATP1C1 characterized in the rat (Sugiyama 
et al., 2003). Examples of ubiquitously expressed OATPs are the human OATP2A1, 
OATP3A1 and OATP4A1 whose mRNA was found in essentially all the tissues analyzed 
(Roth et al., 2012). 
 
In humans, the OATP1 family has four members, OATP1A2, OATP1B1, OATP1B3 and 
OATP1C1 (Figure 1). Messenger RNA for SLCO1A2 encoding OATP1A2 has been detected 
in numerous tissues including brain, kidney, liver, lung, testes, placenta and prostate (Roth et 
al., 2012). At the protein level, OATP1A2 has been shown to be expressed in endothelial cells 
of the blood-brain barrier (Bronger et al., 2005; Gao et al., 2000; Lee et al., 2005), at the 
  
brush-border side in the distal nephron (Lee et al., 2005), in cholangiocytes (Lee et al., 2005), 
in the pars plana of the ciliary body epithelium (Gao et al., 2005), and in syncytiotrophoblasts 
(Loubiere et al., 2010) (Figure 2). As already mentioned above, OATP1B1 and OATP1B3 are 
considered to be liver specific transporters (Roth et al., 2012). Under normal conditions they 
are expressed at the sinusoidal membrane of human hepatocytes with OATP1B3 expression 
being stronger around the central vein than around the portal vein (Konig et al., 2000a). In a 
recent study protein expression of OATP1B1 and OATP1B3 was measured using a multiplex 
UPLC-MRM MS method and the results demonstrated that both proteins were found in equal 
amounts in membrane fractions isolated from human hepatocytes (Ji et al., 2012). SLCO1B3 
mRNA and OATP1B3 protein expression was also documented in several cancers (reviewed 
in (Obaidat et al., 2012)) and the high level of mRNA could be due to an alternatively spliced 
variant (Nagai et al., 2012). The last member in the OATP1 family, OATP1C1, is expressed 
in glial cells throughout the hypothalamus (Alkemade et al., 2011), at the blood-brain barrier, 
in the choroid plexus (Roberts et al., 2008), in Leydig cells of testes (Pizzagalli et al., 2002), 
and in the pars plana of the ciliary epithelium (Gao et al., 2005) (Figure 2). 
 
The prostaglandin transporter, OATP2A1, is one of the ubiquitously expressed OATPs. 
SLCO2A1 mRNA has been detected in almost every tissue tested (Roth et al., 2012). At the 
protein level, human OATP2A1 has been shown to be expressed in retinal epithelial cells and 
in epithelial and endothelial cell layers of different eye tissues including the ciliary body 
(Kraft et al., 2010) (Figure 2), in the endometrium (Kang et al., 2005), in neurons, astrocytes, 
and microglia (Choi et al., 2008), as well as in the parietal cells of the gastric corpus and the 
pyloric glands of the antrum (Mandery et al., 2010). The second transporter in the OATP2 
family, OATP2B1 encoded by the SLCO2B1 gene, is also abundantly expressed in multiple 
organs at the mRNA level (Tamai et al., 2000). At the protein level OATP2B1 was detected at 
the sinusoidal membrane of hepatocytes (Kullak-Ublick et al., 2001), at the basolateral 
membrane of syncytiotrophoblasts (St Pierre et al., 2002), at the brush-border membrane in 
the small intestine (Kobayashi et al., 2003), in keratinocytes (Schiffer et al., 2003), in the 
mammary gland (Pizzagalli et al., 2003), at the luminal membrane of endothelial cells of the 
blood-brain barrier (Bronger et al., 2005), in the pars plicata and pars plana of the ciliary body 
(Gao et al., 2005; Kraft et al., 2010), in endothelial cells in the heart (Grube et al., 2006b), in 
human platelets (Niessen et al., 2009), and in the skeletal muscle (Knauer et al., 2010) (Figure 
2). 
 
  
SLCO3A1 mRNA levels were found in numerous tissues with highest levels in testes, brain, 
heart and lung (Huber et al., 2007). At the protein level, OATP3A1 is localized in the ciliary 
body epithelium (Gao et al., 2005), testes, in the choroid plexus, in neurons in the frontal 
cortex (Huber et al., 2007) and at the plasma membrane of epithelial cells of the lactiferous 
ducts in normal breast tissue (Kindla et al., 2011). In testes and in the brain two splice variants 
were shown to be expressed in a cell type-specific pattern (Huber et al., 2007). In testes, 
OATP3A1_v1 is expressed in germ cells while OATP3A1_v2 is expressed in Sertoli cells. In 
the choroid plexus variant 1 is expressed at the basolateral membrane while variant 2 is 
expressed at the apical and sub-apical membrane. In the frontal cortex, OATP3A1_v1 is 
localized in neuroglial cells of the grey matter and OATP3A1_v2 in cell bodies and axons of 
the neurons (Huber et al., 2007) (Figure 2). 
 
SLCO4A1 mRNA was found in numerous tissues including the heart, placenta, lung, liver, 
skeletal muscle, kidney and pancreas (Fujiwara et al., 2001; Tamai et al., 2000). At the protein 
level OATP4A1 was detected in the ciliary body epithelium (Gao et al., 2005) and in 
syncytiotrophoblasts (Loubiere et al., 2010; Sato et al., 2003) (Figure 2). Based on northern 
blot analysis, OATP4C1 was predicted to be a kidney-specific transporter (Mikkaichi et al., 
2004) but the human protein has not been localized yet. In addition, microarray studies 
suggest that mRNA from the SLCO4C1 gene is also detectable in the liver (Bleasby et al., 
2006). 
 
SLCO5A1 mRNA was reported in fetal brain, prostate, skeletal muscle and thymus (Bleasby 
et al., 2006). At the protein level, OATP5A1 was detected at the plasma membrane of 
epithelial cells of the lactiferous ducts in normal breast tissue (Kindla et al., 2011). 
 
The expression of SLCO6A1 mRNA was detected in testes, spleen, brain and placenta (Lee et 
al., 2004; Suzuki et al., 2003). The expression of the different OATPs in various tumors has 
recently been summarized (Obaidat et al., 2012). 
 
5. Transport Mechanisms of Oatps 
The mechanism(s) by which OATPs transport is(are) not fully understood, but OATPs are 
believed to act as organic anion exchangers (Hagenbuch and Gui, 2008). In 1997 bicarbonate 
was identified as the first counterion in experiments with rat OATP1A1 expressed in HeLa 
cells (Satlin et al., 1997). Additional experiments demonstrated that reduced glutathione and 
  
glutathione conjugates could act as counter ions. Transport of taurocholate and leukotriene C4 
mediated by rat OATP1A1 was trans-stimulated by glutathione (Li et al., 1998), while 
taurocholate transport by rat OATP1A4, but not by rat OATP1A1, was also trans-stimulated 
by the efflux of a conjugate of glutathione (Li et al., 2000), suggesting that no general 
transport mechanism exists for OATPs. OATP1B3 mediated cotransport of glutathione (Briz 
et al., 2006) could not be confirmed (Mahagita et al., 2007) and such a transport mechanism 
would be hard to reconcile for the uptake of organic anions into hepatocytes given the rather 
steep in-to-out glutathione gradient across the hepatocyte plasma membrane. 
 
Uptake by various OATPs has been shown to be stimulated by a low extracellular pH, such as 
for example transport mediated by OATP2B1, which in expressed among other organs in the 
small intestine (Kobayashi et al., 2003). The influence of extracellular pH was tested with 13 
different OATPs, out of which 12 were stimulated by a low extracellular pH. This stimulation 
was found to be due to a lowered Km value at pH 6.5 compared to pH 7.4 demonstrating 
increased affinity of the transport process at low pH. Mutagenesis of a highly conserved 
histidine in the third transmembrane domain to a glutamine abolished the pH dependency of 
rat OATP1A1. In contrast, replacing the glutamine found at this conserved position in the pH-
insensitive OATB1C1 with a histidine rendered OATP1C1 pH sensitive (Leuthold et al., 
2009). Hence, an acidic microclimate like in the intestine or lowering the pH in the 
microclimate adjacent to OATPs by an active Na+/H+-exchanger could stimulate their 
transport compared to uptake at neutral pH. 
 
In addition to this modulation of transport at low pH, i.e. at higher proton concentrations, a 
similar modulation of OATP mediated substrate uptake by another substrate has also been 
observed. This was first reported for rat OATP1A4, where estradiol-17β-glucuronide 
stimulated transport of taurocholate but not of digoxin (Sugiyama et al., 2002). A similar 
stimulation has also been observed for OATP2B1, where prostaglandins A1 and A2 
stimulated the transport of dehydroepiandrosteron sulfate (Pizzagalli et al., 2003). 
Interestingly, OATP2B1-mediated transport of dehydroepiandrosterone and estrone-3-sulfate 
was stimulated at low progesterone concentrations, while at higher concentrations of 
progesterone as modulator transport activity returned to control values (Grube et al., 2006a). 
In the same study, testosterone and mifepristone inhibited rather than stimulated transport 
activity of OATP2B1. Dietary and herbal components have also been documented to 
stimulate OATP-mediated transport, such as rutin, which stimulated OATP1B1-mediated 
  
dehydroepiandrosterone sulfate uptake (Wang et al., 2005) and green tea extracts or the green 
tea epigallocatechin gallate, which stimulated OATP1B3-mediated uptake of estrone-3-sulfate 
(Roth et al., 2011). Finally, OATP1B3, but not OATP1B1-mediated transport of estradiol-
17β-glucuronide was stimulated by clotrimazole (Gui et al., 2008). However, such a 
stimulation was not observed for estrone-3-sulfate transport, which was not affected by 
clotimazole or for fluo-3 transport, which was inhibited. Several additional drugs tested in this 
study did not stimulate either OATP1B1 or OATP1B3. These results clearly show that 
OATPs have more than one substrate binding site, which may or may not interact with each 
other. This has been formally demonstrated with kinetic experiments that revealed a high and 
a low affinity component for estrone-3-sulfate uptake for OATP1B1 (Gui and Hagenbuch, 
2009; Noe et al., 2007; Tamai et al., 2001). In summary, the transport mechanism of OATPs 
is complex, may vary for the same transporter for different substrates and clearly more work 
is needed to elucidate it in detail. 
 
Understanding the exact transport mechanisms of OATPs is highly relevant as depending on 
the transport mechanism, OATPs may or may not be able to concentrate a substrate within 
cells over the respective extracellular concentration, like for example drugs in hepatocytes. 
For illustration, the concentration of the antidiabetic drug glibenclamide is 50 times higher in 
rat livers than in plasma (Kellner et al., 1969). While glibenclamide has been shown to be 
transported by OATP2B1 (Fuchikami et al., 2006), for OATP1B1 and OATP1B3 only 
inhibition by glibenclamide, but not direct uptake, has been demonstrated (Bednarczyk, 
2010). We would like to emphasize that although such inhibition indicates that glibenclamide 
could be a substrate of OATP1B1 and/or OATT1B3 it does not necessarily imply that it is a 
substrate. This has recently been worked out for the liver function test marker indocyanine 
green, which is a potent inhibitor of all three hepatocellular OATPs and of the sodium 
taurocholate cotransporting polypeptide NTCP, but is only transported by NTCP and 
OATP1B3 (de Graaf et al., 2011). 
 
6. Regulation of expression and modulation of function: 
Regulation of OATP expression has been documented at the transcriptional as well as at the 
post-translational level. Early studies demonstrated that expression of the liver specific 
OATP1B1 and OATP1B3 was controlled by the liver enriched hepatocyte nuclear factor 1α 
(HNF1α) (Jung et al., 2001). In hepatocellular carcinoma (HCC), expression of OATP1B3 
was shown to be decreased while expression of OATP1B1 was normal at the mRNA level or 
  
slightly decreased at the protein level (Cui et al., 2003; Vavricka et al., 2004). It was also 
shown that HNF3β, which was overexpressed in HCC, could repress transcriptional 
expression of OATP1B3 but not of OATP1B1, potentially explaining the selective down-
regulation of OATP1B3 in HCC (Vavricka et al., 2004). It is interesting to note that in ovarian 
cancer, but not in healthy ovarian tissue, expression of the liver specific OATP1B1 and 
OATP1B3 was reported (Svoboda et al., 2011). In addition several transcription factors in the 
family of the nuclear receptors have been shown to regulate OATP expression. Studies in 
breast carcinoma and breast cancer cell lines demonstrated a positive correlation between 
human PXR and OATP1A2 expression (Miki et al., 2006). This correlation was confirmed 
and a direct effect of PXR activity on OATP1A2 expression could be demonstrated (Meyer zu 
Schwabedissen et al., 2008). The same study also confirmed that the SLCO1A2 promoter 
could be activated by the constitutive androstane receptor (CAR) (Meyer zu Schwabedissen et 
al., 2008). Using isolated human hepatocytes it was shown that treatment with the prototypic 
activator of the aryl hydrocarbon receptor (AhR) 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
and with the CAR activator phenobarbital resulted in a decreased expression of OATP1B3 
and OATP2B1 (Jigorel et al., 2006). The promoter of human SLCO4C1 was also activated via 
AhR by 3-methylcholanthrene and by fluvastatin (Suzuki et al., 2011). Oltipraz, which 
activates NFE2-related factor 2 (Nrf2), also down-regulated OATP1B3, while the PXR 
agonist rifampicin led to an increase of OATP1B1 (Suzuki et al., 2011). Furthermore, 
OATP1B1 was shown to be regulated by the liver receptor α (LXRα) and by the farnesoid X 
receptor (FXR) (Meyer Zu Schwabedissen et al., 2010) and earlier it was also shown that 
OATP1B3 is under the control of FXR (Jung et al., 2002). In addition to these studies there 
are many other reports that show that OATP expression is influenced by different growth 
factors, cytokines and chemicals. Hepatocyte growth factor (HGF) down-regulated SLCO1B1 
and SLCO2B1 mRNA and protein while mRNA for SLCO1B3 was not affected (Le Vee et al., 
2009). Similarly, down-regulation of SLCO1B1, SLCO1B3 and SLCO2B1 mRNA as well as 
OATP1B1 at the protein level was shown by interleukin 1β (Le Vee et al., 2008). 
 
Post-translational regulation was demonstrated for OATP2B1. Protein kinase C activation by 
a phorbol ester resulted in increased phosphorylation of OATP2B1 with a decrease in 
maximal transport rate suggesting a rapid internalization of the transporter (Kock et al., 2010). 
 
All these regulations at the transcriptional and post-translational levels could lead to increased 
or decreased OATP-mediated uptake. However, as outlined above, modulation of OATP-
  
mediated transport could also be due to direct effects of substances, e.g. by acting from the 
cis-side either as inhibitors or as stimulators of substrate transport. Furthermore, several of 
these modulators have been shown to act in a substrate-dependent way, making predictions of 
potential interactions more complicated. For example, rifampicin at 10 µM had no effect on 
OATP1B1-mediated uptake of bromosulfophthalein (BSP) (Vavricka et al., 2002) but 
inhibited estradiol-17β-glucuronide uptake by 90 % (Tirona et al., 2003). In another study, 
100 µM gemfibrozil inhibited OATP1B1-mediated uptake of taurocholate, fluvastatin and 
simvastatin by about 60 % but had no effect on the uptake of estrone-3-sulfate or troglitazone-
sulfate (Noe et al., 2007). Clotrimazole, epigallocatechin gallate, diclofenac and ibuprofen are 
among the chemicals that have been shown to have stimulatory, inhibitory or no effects on 
OATP-mediated transport in a substrate-dependent way (Gui et al., 2008; Kindla et al., 2011; 
Roth et al., 2011). Thus, because the molecular mechanisms of these modulations are not 
known yet it is crucial to test more than just a single OATP substrate when screening for 
potential interactions, e.g. to predict pharmacokinetic interactions during drug development. 
 
7. Structure function relationship: 
Based on hydrophobicity analyses, experimental data available from rat OATP1A1 
(Jacquemin et al., 1994; Wang et al., 2008) and homology modeling, OATPs are 12 
transmembrane domain proteins with the amino- and the C-terminal ends located at the 
cytoplasmic side of the membrane (Figure 3A). Because so far no crystal structure data are 
available, homology modeling was used to predict a putative three-dimensional model (Figure 
3B). Furthermore, several groups have used chimeric approaches combined with site-directed 
mutagenesis and homology modeling to investigate what regions or what amino acids would 
be important for OATP function. Based on such studies it became clear that cysteine residues 
in the large extracellular loop 5 are involved in disulfide bonds and are required for proper 
surface expression of OATP2B1 (Hanggi et al., 2006) (Figure 3A). Transmembrane domains 
1, 8, 9 and 10 as well as extracellular loop 6 have been shown to be important for OATP1B1 
and OATP1B3 substrate transport (Degorter et al., 2012; Gui and Hagenbuch, 2008, 2009; 
Miyagawa et al., 2009). Furthermore, site-directed mutagenesis of conserved positively 
charged amino acids identified several residues in transmembrane domains 1, 7 and 10 that 
affect substrate transport in OATP1B1 and OATP1B3 (Glaeser et al., 2010; Mandery et al., 
2011; Weaver and Hagenbuch, 2010). A recent study demonstrated that when the three amino 
acids A45, L545 and T615 in OATP1B1 were replaced to their corresponding residues in 
OATP1B3, OATP1B1 was able to transport the OATP1B3-selective substrate 
  
cholecystokinin-8 (CCK-8) (Degorter et al., 2012), suggesting that these amino acids are 
indeed involved in substrate recognition or transport by OATP1B3. These studies are 
important because they will help to eventually understand the molecular mechanisms of the 
broad substrate specificity of OATPs and potentially allow predicting and thus preventing 
drug-drug interactions at the OATP levels. 
 
8. Mutations and Polymorphisms of OATPs 
So far, few pathophysiologic conditions related to mutations in SLCO genes have been 
reported. Mesolemia-synosteses syndrome (OMIM600383) is a rare disease and includes 
mesomelic limb shortening and acral synosthoses (Isidor et al., 2009). This syndrome has 
been linked to a disturbance in sulfate metabolism and/or homoestasis (Dawson, 2011). 
Cytogenetic analysis of 5 patients from four families with this disease identified a 
submicroscopic microdeletion on chromosome 8q13 (Isidor et al., 2010). This deletion spans 
the two genes SULF1 (heparin sulphate 6-O-endosulfatase 1) and SLCO5A1 (OATP5A1). 
OATP5A1 is expressed in adult heart and in fetal brain and heart (Isidor et al., 2010), but its 
function has not been characterized so far. As in all patients deletions spanned both the 
SULF1 and the SLCO5A1 gene, the contribution of missing or malfunctioning OATP5A1 
remains to be worked out, in particular as in a single healthy individual a partial deletion of 
SLCO5A1 was reported (de Smith et al., 2007). Rotor syndrome is a rare, benign syndrome 
presenting with conjugated and unconjugated hyperbilirubinemia in conjunction with 
coproporphyrinuria and a massively altered BSP clearance (Strassburg, 2010). Its inheritance 
is autosomal recessive. A recent investigation of individuals with Rotor syndrome from eight 
different families revealed mutations in the SLCO1B1 and SLCO1B3 genes, rendering the 
respective OATPs non-functional (van de Steeg et al., 2012). Mice with a disrupted Slco1a/1b 
locus also presented with unconjugated and conjugated hyperbilirubinemia. (van de Steeg et 
al., 2012). A study with healthy volunteers associated elevated conjugated and unconjugated 
bilirubin with the *15 allele of SLCO1B1, which is known to display reduced transport 
activity of the corresponding protein (Zhang et al., 2007). A study investigating the effect of 
the p.V174A variant of OATP1B1 on thyroid and estrogen metabolite levels in serum found 
total bilirubin, estrone-3-sulfate and thyroxine sulphate levels to be higher in individuals with 
the p.174A variant (van der Deure et al., 2008a). A genome-wide association study associated 
SLCO1B3 variants with elevated total and unconjugated serum bilirubin (Sanna et al., 2009), 
while a meta-analysis of three studies associated a SLCO1B1 variant with elevated serum 
bilirubin (Johnson et al., 2009). The finding of the latter study was recently confirmed in an 
  
independent genome-wide association study (Bielinski et al., 2011). Hence, there is now 
ample genetic evidence for a role of OATP1B1 and OATP1B3 in hepatocellular uptake of 
unconjugated and conjugated bilirubin. Finally, serum levels of reverse triiodothyronine have 
also been reported to be elevated in carriers of the OAPT1A2 p.172D variant (van der Deure 
et al., 2010). 
 
A genome-wide association study in a cohort of individuals with progressive supranuclear 
palsy found a suggestive association with SLCO1A2 in addition to other loci (Hoglinger et al., 
2011). Additionally, a genome-wide association study of Crohn's diseases in an Ashekenazi 
Jewish population found a variant of the SLCO6A1 to be disease associated (Kenny et al., 
2012). 
 
While evidence for the involvement of SLCO genes in the pathogenesis of diseases is starting 
to emerge, a multitude of studies have investigated the role of SLCO variants on drug 
disposition with a particular focus on pharmacokinetics of drugs. Many reviews have covered 
the role of genetic SLCO variants on pharmacokinetics of drugs (Fahrmayr et al., 2010; 
Franke et al., 2010; Kerb, 2006; Konig, 2011; Niemi et al., 2011; Sissung et al., 2010; Stieger 
and Meier, 2011; Zair et al., 2008). Understanding the impact of SLCO pharmacogenomics is 
not only relevant for understanding alterations in pharmacokinetics of drugs in patients with 
different SLCO genotypes (Kalliokoski and Niemi, 2009), but also contributes to an 
understanding of adverse drug reactions. This is exemplified in the case of SLCO1B1, which 
in an elegant genome-wide association study was associated with simvastatin-induced 
myotoxicity (Link et al., 2008). This and other studies have been the basis to suggest a dosing 
regimen for statins, which takes the SLCO1B1 genotype into account (Niemi, 2010). 
 
9. Conclusion and Outlook 
Since the cloning of the first OATP, the SLCO family members have made it to center stage 
in drug development (Giacomini et al., 2010) and in the understanding of drug disposition 
(Fenner et al., 2012). While the progress in developing tools for understanding the role of 
OATPs in handling of endo- and xenobiotics has been enormous, knowledge on their 
molecular transport mechanisms and on their structure is clearly lagging behind. Both areas 
are however highly relevant for developing better models to predict their impact in physiology 
and pathophysiology as well as in drug disposition. In addition, OATPs are increasingly 
  
recognized as important transporters in cancer therapy (Obaidat et al., 2012) and in 
understanding clearance tests like e.g. liver function tests (Stieger et al., 2012). 
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Table 1: The human members of the organic anion transporting superfamily  
New gene 
symbol 
New protein 
name 
Predominant 
substrates 
Tissue distribution/subcellular 
expression 
Link to disease Human gene 
locus 
Sequence 
Accession ID 
Splice variants 
SLCO1A2 OATP1A2 Bile salts, 
organic anions 
and cations 
Brain (endothelial cells), 
kidney (apical), intestine 
(apical), liver 
(cholangiocytes), eye (ciliary 
body) 
 12p12 NM_021094 
NM_134431 
2 splice variants 
SLCO1B1 OATP1B1 Bile salts, 
organic anions 
Liver (hepatocytes) (Statin-induced 
myopathy, Rotor 
Syndrome) 
12p NM_6446  
SLCO1B3 OATP1B3 Bile salts, 
organic anions 
Liver (hepatocytes) (Unconjugated 
hyperbilirubinemia, 
Rotor syndrome) 
12p12 NM_019844  
SLCO1C1 OATP1C1 T4,T3, rT3 Brain (blood-brain barrier), 
testis (Leydig cells) 
 12p12.2 NM_017435 
NM_001145944 
NM_001145945 
NM_001145946 
4 splice variants 
SLCO2A1 OATP2A1 Prostaglandins 
(C/lactate) 
Ubiquitous  3q21 NM_005630  
SLCO2B1 OATP2B1 E-3-S, DHEAS Liver (hepatocytes), placenta, 
intestine (apical), eye (ciliary 
body) 
 11q13 NM_007256 
NM_001145211 
NM_001145212 
3 splice variants 
  
Table 2: Endogenous substrates of organic anion transporting polypeptides 
If Km-values are available, data demonstrating transport are omitted. Endogenous 
concentrations are given for systemic concentration and are, due to space reasons, not 
necessarily found in the references given in this table. The concentrations found for many 
substances in plasma vary widely (in some instances more than factor of 10). In addition, 
many of the listed substance have a considerable binding to plasma proteins. Consequently, 
the values given should only be taken as approximate. 
 
Transporter Substrate Affinity Plasma 
concentration 
Reference 
Rat     
OATP1A1 cholate 54 µM ~ 3 µM (Eckhardt et al., 
1999) 
 taurocholate 32 – 50 
µM 
~ 1 µM (Eckhardt et al., 
1999; Kullak-
Ublick et al., 1994; 
Satlin et al., 1997) 
 glycocholate 54 µM ~ 0.1 µM (Eckhardt et al., 
1999) 
 taurochenodeoxycholate 7 µM ~ 0.1 µM (Eckhardt et al., 
1999) 
 tauroursodeoxycholate 13 µM ~ 0.01 µM (Eckhardt et al., 
1999) 
 bilirubinmonoglucuronide  ~ 1 µM  (Reichel et al., 
1999) 
 dehydroepiandrostenone 
sulfate 
5 µM ~ 0.1 nM (Eckhardt et al., 
1999) 
 aldosterone 15 nM ~ 0.1 nM (Bossuyt et al., 
1996a) 
 cortisol 13 µM ~ 0.1 µM (Bossuyt et al., 
1996a) 
 estradiol-17β-glucuronide 3 - 20 
µM 
 (Bossuyt et al., 
1996a; Eckhardt et 
al., 1999; Ishizuka 
  
et al., 1998; 
Kouzuki et al., 
1999) 
 Estrone-3-sulfate 5 - 12 
µM 
 (Bossuyt et al., 
1996a; Eckhardt et 
al., 1999) 
 Leukotriene C4  ~ 1 pM (Li et al., 1998) 
 diiodothyronine (T2)   (Friesema et al., 
1999) 
 diiodothronine sulfate (T2S)   (Friesema et al., 
1999) 
 prostaglandine E2 pH 6.5 ~ 1 nM (Leuthold et al., 
2009) 
 triiodothyronine (T3)  ~ 1 nM (Friesema et al., 
1999) 
 triiodothyronine sulfate (T3S)  ~ 0.1 nM (Friesema et al., 
1999) 
 reverse triiodothyronine (rT3)  ~ 0.01 nM (Friesema et al., 
1999) 
 reverse triiodothyronine 
sulfate (rT3S) 
 ~ 0.1 nM (Friesema et al., 
1999) 
 thyroxine (T4)  ~ 50 nM (Friesema et al., 
1999) 
 thyroxine sulphate (T4S)  ~ 0.05 nM (Friesema et al., 
1999) 
     
OATP1A3 taurocholate 10-31 
µM 
~ 1 µM (Masuda et al., 
1999; Takeuchi et 
al., 2001) 
 dehydroepiandrostenone 
sulfate 
9 – 17 
µM 
~ 0.1 nM (Reichel et al., 
1999; Takeuchi et 
al., 2001) 
 estradiol-17β-glucuronide 3-35 µM  (Noe et al., 1997; 
Takeuchi et al., 
  
2001) 
 estrone-3-sulfate 11-15 
µM 
 Noe, 1997 
#333}(Takeuchi et 
al., 2001) 
 thyroxine (T4) 7-20 µM ~ 50 nM Abe, 1999 
#670}(Takeuchi et 
al., 2001) 
 triiodothyronine (T3) 6-44 µM ~ 1 nM (Abe et al., 1999; 
Takeuchi et al., 
2001) 
     
OATP1A4 cholate 46 µM ~ 3 µM (Noe et al., 1997) 
 taurocholate 35 - 36 
µM 
~ 1 µM (Abe et al., 1999; 
Noe et al., 1997) 
 glycocholate 40 µM ~ 0.1 µM (Reichel et al., 
1999) 
 taurochenodeoxycholate 12 µM ~ 0.1 µM (Reichel et al., 
1999) 
 tauroursodeoxycholate 17 µM ~ 0.01 µM (Reichel et al., 
1999) 
 dehydroepiadrostenone 
sulfate 
17 µM ~ 0.1 nM (Reichel et al., 
1999) 
 estradiol-17β-glucuronide 3 µM  (Noe et al., 1997) 
 estrone-3-sulfate 11 µM  (Noe et al., 1997) 
 prostaglandine E2 pH 6.5 ~ 5 nM (Leuthold et al., 
2009) 
 triiodothyronine (T3) 6 µM ~ 1 nM (Abe et al., 1999) 
 thyroxine (T4) 7 µM ~ 50 nM (Abe et al., 1999) 
     
OATP1A5 cholate 9 µM ~ 3 µM (Walters et al., 
2000) 
 taurocholate 18 – 30 
µM 
~ 1 µM (Abe et al., 1999; 
Walters et al., 
  
2000) 
 glycocholate 15 µM ~ 0.1 µM (Walters et al., 
2000) 
 taurochenodeoxycholate 7 µM ~ 0.1 µM (Walters et al., 
2000) 
 glycochenodeoxycholate 6 µM  (Walters et al., 
2000) 
 tauroursodeoxycholate 7 µM ~ 0.01 µM (Walters et al., 
2000) 
 glycoursodeoxycholate 5 µM  (Walters et al., 
2000) 
 taurodeoxycholate 6 µM ~ 0.1 µM (Walters et al., 
2000) 
 glycodeoxycholate 4 µM  (Walters et al., 
2000) 
 dehydroepiandrostenone 
sulfate 
162 µM ~ 0.1 nM (Cattori et al., 
2001) 
 estradiol-17β-glucuronide 39 µM  (Cattori et al., 
2001) 
 estrone-3-sulfate 268 µM  (Cattori et al., 
2001) 
 leukotriene C4  ~ 1 pM (Cattori et al., 
2001) 
 prostaglandine E2 35 µM ~ 5 nM (Cattori et al., 
2001) 
 thyroxine (T4) 5 µM ~ 50 nM (Abe et al., 1999) 
 triiodothyronine (T3) 7 µM ~ 1 nM (Abe et al., 1999) 
     
OATP1B2 taurocholate 9 – 27 
µM 
~ 1 µM (Cattori et al., 
2000; Kakyo et al., 
1999) 
 dehydroepiadrostenone 
sulfate 
5 µM ~ 0.1 nM (Cattori et al., 
2001) 
  
 estradiol-17β-glucuronide 32 µM  (Cattori et al., 
2001) 
 estrone-3-sulfate 37 µM  (Cattori et al., 
2001) 
 arachidonate 96 µM ~ 10 µM (Kanai et al., 1995) 
 CCK8 15 µM ~ 1 pM (Ismair et al., 
2001) 
 leukotriene C4 7 µM ~ 1 pM (Cattori et al., 
2001) 
 prostaglandine E2 13 µM ~ 5 nM (Cattori et al., 
2001) 
 triiodothyronine (T3)  ~ 1 nM (Cattori et al., 
2000) 
 thyroxine (T4)  ~ 50 nM (Cattori et al., 
2000) 
     
OATP1C1 taurocholate  ~ 1 µM (Sugiyama et al., 
2003) 
 CCK-8  ~ 1 pM (Sugiyama et al., 
2003) 
 estradiol-17β-glucuronide 11 µM  (Sugiyama et al., 
2003) 
 estrone  ~ 0.1 nM (Sugiyama et al., 
2003) 
 estrone-3-sulfate   (Sugiyama et al., 
2003) 
 dehydroepiandrostenone 
sulfate 
 ~ 0.1 nM (Sugiyama et al., 
2003) 
 dihydrotestosterone  ~ 1 nM (Sugiyama et al., 
2003) 
 leukotriene C4  ~ 1 pM (Sugiyama et al., 
2003) 
 leukotriene E4   (Sugiyama et al., 
  
2003) 
 testosterone  ~ 10 nM (Sugiyama et al., 
2003) 
 thyroxine (T4) 180 nM ~ 50 nM (Sugiyama et al., 
2003) 
 reverse triiodothyronine (rT3)  ~ 0.01 nM (Sugiyama et al., 
2003) 
 triiodothyronine (T3)  ~ 1 nM (Sugiyama et al., 
2003) 
     
OATP2A1 arachidonate 96 µM ~ 10 µM (Kanai et al., 1995) 
 6-keto prostaglandine F1α 8 µM ~ 1 nM (Kanai et al., 1995) 
 prostaglandine E1 70 nM  (Kanai et al., 1995) 
 prostaglandine E2 94 nM ~ 0.1 nM (Kanai et al., 1995) 
 prostaglandine E2α 104 nM  (Kanai et al., 1995) 
 thromboxane B2 423 nM ~ 1 nM (Kanai et al., 1995) 
     
OATP2B1 taurocholate 18 µM ~1 µM (Nishio et al., 
2000) 
 leukotriene C4 3 µM ~ 1 pM (Nishio et al., 
2000) 
 prostaglandin D2 18 µM ~ 10 nM (Nishio et al., 
2000) 
 prostaglandin E1   (Nishio et al., 
2000) 
 prostaglandin E2  ~ 0.1 nM (Nishio et al., 
2000) 
 thromboxane B2  ~ 1 nM (Nishio et al., 
2000) 
     
OATP4A1 taurocholate  ~ 1 µM (Fujiwara et al., 
2001) 
 triiodothyronine (T3)  ~ 1 nM (Fujiwara et al., 
  
2001) 
     
OATP4C1 triiodothyronine /T3) 2 µM ~ 1 nM (Mikkaichi et al., 
2004) 
     
OATP6B1 taurocholate 9 µM ~ 1 µM (Suzuki et al., 
2003) 
 dehydroepiandrostenone 
sulfate 
26 µM ~ 0.1 nM (Suzuki et al., 
2003) 
 thyroxine (T4) 6 µM ~ 50 nM+ (Suzuki et al., 
2003) 
 triiodothyronine (T3)  ~ 1 nM (Suzuki et al., 
2003) 
     
OATP6C1 taurocholate 3 µM ~ 1 µM (Suzuki et al., 
2003) 
 dehydroepiandrostenone 
sulfate 
22 µM ~ 0.1 nM (Suzuki et al., 
2003) 
 thyroxine (T4) 6 µM ~ 50 nM (Suzuki et al., 
2003) 
 triiodothyronine (T3)  ~ 1 nM (Suzuki et al., 
2003) 
     
human     
OATP1A2 cholate 93 µM ~ 1 µM (Kullak-Ublick et 
al., 1995) 
 taurocholate 60 µM ~ 0.1 µM (Kullak-Ublick et 
al., 1995) 
 glycocholate  ~ 0.5 µM (Kullak-Ublick et 
al., 1995; Kullak-
Ublick et al., 2001) 
 taurochenodeoxycholate  ~ 0.5 µM (Kullak-Ublick et 
al., 1995) 
  
 tauroursodeoxycholate 19 ~ 0.001 µM (Kullak-Ublick et 
al., 1995) 
 bilirubin  ~ 10 µM (Briz et al., 2003) 
 estradiol-17β-glucuronide   (Briz et al., 2003; 
Kullak-Ublick et 
al., 2001) 
 estrone-3-sulfate 16 - 59 ~ 2 nM (Bossuyt et al., 
1996b; Lee et al., 
2005) 
 dehydroepiandrostenone 
sulfate 
7 µM ~ 5 µM (Kullak-Ublick et 
al., 1998) 
 prostaglandin E2  ~ 1 nM (Kullak-Ublick et 
al., 2001) 
 reverse triiodothyronine (rT3)  ~ 0.1 nM (Fujiwara et al., 
2001) 
 triiodothyronine (T3) 7 µM ~ 1 nM (Fujiwara et al., 
2001) 
 triiodothyronine sulfate (T3S)  ~ 0.1 nM (van der Deure et 
al., 2010) 
 thyroxine (T4) 8 µM ~ 100 nM (Fujiwara et al., 
2001) 
 thyroxine sulfate (T4S)  ~ 10 pM (van der Deure et 
al., 2010) 
     
OATP1B1 cholate 11 µM ~ 1µM (Cui et al., 2001) 
 taurocholate 10 – 34 
µM 
~ 0.1 µM (Abe et al., 1999; 
Cui et al., 2001; 
Hsiang et al., 
1999) 
 glycocholate  ~ 0.5 µM (Kullak-Ublick et 
al., 2001) 
 tauroursodeoxycholate 7 µM ~ 0.001 µM (Maeda et al., 
2006) 
  
 glycoursodeoxycholate 5 µM ~ 0.1 µM (Maeda et al., 
2006) 
 bilirubin 8 – 160 
nM 
~ 10 µM (Briz et al., 2003; 
Cui et al., 2001) 
 bilirubinmonoglucuronide 100 nM ~ 1 µM (Cui et al., 2001) 
 bilirubindiglucuronide 280 nM ~ 1 µM (Cui et al., 2001) 
 estradiol-17β-glucuronide 4- 14 µM  (Cui et al., 2001; 
Hirano et al., 2004; 
Konig et al., 
2000b; Nakai et 
al., 2001; Tamai et 
al., 2001) 
 estrone-3-sulfate 458 nM - 
13 µM 
68 -94 
nM and 5 
- 7µM 
~ 2 nM (Cui et al., 2001; 
Hirano et al., 
2004) 
(Tamai et al., 
2001) 
 dehydroepianstrostenone 
sulfate 
22 µM ~ 5 µM (Cui et al., 2001) 
 leukotriene C4  ~ 10 pM (Abe et al., 1999; 
Kullak-Ublick et 
al., 2001) 
 leukotriene E4  ~ 0.1 nM (Abe et al., 1999) 
 prostaglandine E2  ~ 1 nM (Abe et al., 1999; 
Kullak-Ublick et 
al., 2001; Tamai et 
al., 2000) 
 reverse triiodothyronine 
sulphate (rT3S) 
 ~ 10 nM (van der Deure et 
al., 2008a) 
 triiodothyronine (T3) 3 µM ~ 1 nM (Abe et al., 1999) 
 triiodothyronine sulphate 
(T3S) 
 ~ 0.1 nM (van der Deure et 
al., 2008a) 
 thyroxine (T4) 3 µM ~ 100 nM (Abe et al., 1999) 
  
 thyroxine sulphate (T4S)  ~ 10 pM (van der Deure et 
al., 2008a) 
 thromboxane B2  ~ 0.1 nM (Abe et al., 1999) 
     
OATP1B3 cholate 42 µM ~ 1 µM (Briz et al., 2006) 
 taurocholate 6 - 42 
µM 
~ 0.1 µM (Abe et al., 2001; 
Briz et al., 2006) 
 glycocholate 43 µM ~ 0.5 µM (Briz et al., 2006) 
 taurochenodeoxycholate  ~ 0.5 µM (Briz et al., 2006) 
 tauroursodeoxycholate 16 µM ~ 0.001 µM (Maeda et al., 
2006) 
 glycoursodeoxycholate 25 µM ~ 0.1 µM (Maeda et al., 
2006) 
 taurodeoxycholate  ~ 0.5 µM (Briz et al., 2006) 
 bilirubin 39 nM ~ 10 µM (Briz et al., 2003) 
 bilirubinmonoglucuronide 500 nM ~ 1 µM (Cui et al., 2001) 
 CCK8 4 - 11 
µM 
~ 1 pM (Hirano et al., 
2004; Ismair et al., 
2001) 
 dehydroepiandrostenone 
sulfate 
 ~ 5 µM (Konig et al., 
2000a) 
 estradiol-17β-glucuronide 5 – 25 
µM 
 (Cui et al., 2001; 
Hirano et al., 2004; 
Konig et al., 
2000a) 
 estrone-3-sulfate 73 µM 
(pH 8.0) 
55 µM 
(pH 6.5) 
~ 2 nM (Leuthold et al., 
2009) 
 dehydroepiandrostenone 
sulfate 
> 30 
µM 
~ 5 µM (Cui et al., 2001) 
 glutathione 5 µM  (Briz et al., 2006) 
 leukotriene C4  ~ 10 pM (Konig et al., 
  
2000a; Kullak-
Ublick et al., 2001) 
 prostaglandine E2  ~ 1 nM (Kullak-Ublick et 
al., 2001; Tamai et 
al., 2000) 
 triiodothyronine (T3) 6 µM ~ 1 nM (Abe et al., 2001) 
 thyroxine (T4)  ~ 100 nM (Kullak-Ublick et 
al., 2001) 
     
OATP1C1 taurocholate  ~ 0.1 µM (Leuthold et al., 
2009) 
 estradiol-17β-glucuronide   (Pizzagalli et al., 
2002) 
 estrone-3-sulfate  ~ 2 nM (Pizzagalli et al., 
2002) 
 reverse triiodothyronine (rT3) 128 nM ~ 0.1 nM (Pizzagalli et al., 
2002) 
 thyroxine (T4) 90 – 120 
nM 
~ 100 nM (Pizzagalli et al., 
2002; van der 
Deure et al., 
2008b) 
 thyroxine sulfate (T4S) 3 µM ~ 10 pM (van der Deure et 
al., 2008b) 
 triiodothyronine (T3)  ~ 1 nM (Pizzagalli et al., 
2002) 
     
OATP2B1 taurocholate 72 µM 
(pH 5.0) 
~ 0.1 µM (Nozawa et al., 
2004) 
 estrone-3-sulfate 5 – 21 
µM 
~ 2 nM (Kullak-Ublick et 
al., 2001; Tamai et 
al., 2001) (Grube 
et al., 2006a; 
Hirano et al., 2006; 
  
Nozawa et al., 
2004; Pizzagalli et 
al., 2003) 
 dehydroepadrostenone sulfate 9 µM ~ 5 µM (Pizzagalli et al., 
2003) 
 prostaglandine E2  ~ 1 nM (Tamai et al., 
2000) 
 tyroxine (T4) 770 nM 
(pH 8.0) 
310 nM 
(pH 6.5) 
~ 100 nM (Leuthold et al., 
2009) 
     
OATP2A1 prostaglandin D2   (Lu et al., 1996) 
 prostaglandin E1   (Lu et al., 1996) 
 prostaglandin E2  ~ 1 nM (Kraft et al., 2010; 
Lu et al., 1996) 
 prostaglandin F2α  ~ 10 pM (Lu et al., 1996) 
 thromboxane B2  ~ 0.1 nM (Lu et al., 1996) 
     
OATP3A1 estrone-3-sulfate  ~ 2 nM (Tamai et al., 
2000) 
 prostaglandine E1 59 mM  (Adachi et al., 
2003) 
 prostaglandine E2 56 nM ~ 1 nM (Adachi et al., 
2003) 
 prostaglandine F2   (Adachi et al., 
2003) 
     
OATP3A1_
v1 
estrone-3-sulfate pH 6.5 ~ 2 nM (Leuthold et al., 
2009) 
 prostaglandine E1 101 nM  (Huber et al., 
2007) 
 prostaglandine E2 218 nM ~ 1 nM (Huber et al., 
  
2007) 
 tyroxine (T4)  ~ 100 nM  
 vasopressin  ~ 1 pM (Huber et al., 
2007) 
     
OATP3A1_
v2 
arachidonate  ~ 0.1 nM (Huber et al., 
2007) 
 estrone-3-sulfate pH 6.5 ~ 2 nM (Leuthold et al., 
2009) 
 prostaglandine E1 218 nM  (Huber et al., 
2007) 
 prostaglandine E2 371 nM ~ 1 nM (Huber et al., 
2007) 
 tyroxine (T4) pH 6.5 ~ 100 nM (Leuthold et al., 
2009) 
 vasopressin  ~ 1 pM (Huber et al., 
2007) 
     
OATP4A1 taurocholate 15 µM ~ 0.1 µM (Fujiwara et al., 
2001) 
 estradiol-17β-glucuronide   (Tamai et al., 
2000) 
 estrone-3-sulfate  ~ 2 nM (Tamai et al., 
2000) 
 prostaglandine E2  ~ 1 nM (Tamai et al., 
2000) 
 triiodothyronine (T3) 1 µM ~ 1 nM (Fujiwara et al., 
2001) 
 reverse triiodothyronine (rT3)  ~ 0.1 nM (Fujiwara et al., 
2001) 
 thyroxine (T4)  ~ 100 nM (Fujiwara et al., 
2001) 
     
  
OATP4C1 glycoycholate  ~ 0.5 µM (Yamaguchi et al., 
2010) 
 chenodeoxycholate  ~ 0.5 µM (Yamaguchi et al., 
2010) 
 cAMP  ~ 10 nM (Mikkaichi et al., 
2004) 
 estrone-3-sulfate 27 µM ~ 2 nM (Yamaguchi et al., 
2010) 
 triiodothyronine (T3) 6 µM ~ 1 nM (Mikkaichi et al., 
2004) 
 tyroxine (T4)  ~ 100 nM (Mikkaichi et al., 
2004) 
 
Figure legends 
 
Figure 1: Phylogenetic tree and classification of 70 members of the OATP/SLCO superfamily 
of transporters. Human (all capitalized OATP), monkey (maOATP), dog (dOATP), pig 
(sOATP), rat (rOATP) and mouse (mOATP) proteins are grouped into families (with more 
than 40% amino acid sequence identity) and subfamilies (with more than 60% amino acid 
sequence identity). 
 
Figure 2: Distribution of OATPs in selected human epithelial tissues. The OATPs within the 
same subfamily are labelled with the same color. For more details see text. 
 
Figure 3: Topology models for OATP1B1. A) The predicted secondary structure model for 
OATP1B1 is shown with 12 transmembrane domains. The extracellular conserved cysteine 
residues are labelled in black. B) Homology modelling was performed as described (Roth et 
al., 2012) based on the E. coli glycerol-3-phosphate transporter. OATP1B1 is shown from the 
extracellular side (left) and from within the lipid bilayer (right). Colors of the transmembrane 
domains match the colors used in the secondary structure model.  
 
 




